Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study

Journal article

Introduction. Guselkumab (Tremfya®) is an injectable solution used to treat moderate to severe psoriasis and is recommended for patients who are candidates for systemic treatment or phototherapy [1]. It is an immunosuppressive medication that acts on the cytokine IL-23, involved in the regulation of the inflammatory response [2]. Being a new medication, there is an opportunity to carry out a review without bias, in addition to exposing those present in the selected articles. Goal.  To analyze...

Expand abstract

Authors: Schett, G; Chen, W; Gao, S; Chakravarty, SD; Shawi, M

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: BioMed Central
• Journal: Arthritis Research & Therapy
• Volume: 25
• Issue: 1
• Pages: 150-150
• Article number: 150
• Publication date: 2023-08-16
• DOI: 10.1186/s13075-023-03125-4
• EISSN: 1478-6362
• ISSN: 1478-6354
• Language: Portuguese
• Keywords: Arthritis; Interleukin 23; Internal medicine; Medicine; Psoriasis Area and Severity Index; Oncology; Interleukin; Tumor necrosis factor alpha; Adalimumab; Biomarker; Cytokine; Immunology; Gastroenterology; Rheumatology; Psoriatic arthritis; Etanercept; Psoriasis